Drugs / MVA-BN-HIV
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05769569 | Sep 2023 → Jul 2025 | HIV infectious disease | Henry M. Jackson Foundation for the Advancement of Military Medicine | Withdrawn | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04983030 | Apr 2022 → Feb 2026 | AIDS, acquired immunodeficiency | Boris Juelg, MD PhD | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MVA-BN-HIV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04983030 ↗ |
| Modality | Vaccine | “MVA-BN-HIV is a monovalent vaccine comprising a single Modified Vaccinia Ankara - Bavarian Nordic (MVA-BN®) vector encoding Mos1.Env, Mos2S.Env, Mos1.Gag-Pol, and Mos2.Gag-Pol...” NCT04983030 ↗ |